DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control (Q38922177)

7 September 2017

1 reference

title

DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control (English)

1 reference

7 September 2017

0 references

Eun Ju Bae

1

1 reference

7 September 2017

9 August 2016

1 reference

Archives of Pharmacal Research

7 September 2017

1 reference

7 September 2017

39

1 reference

7 September 2017

1114-1128

1 reference

7 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1007/s12272-016-0813-x

7 September 2017

0 references

cites work

Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

IKK-beta links inflammation to obesity-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

On the origin of serum CD26 and its altered concentration in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Inflammation and lipid signaling in the etiology of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Structure and function in dipeptidyl peptidase IV and related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Sitagliptin exerts an antinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The role of metformin in the management of NAFLD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Macrophages, immunity, and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

The effect of glucagon-like peptide 1 on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

21 January 2018

Incretin-based therapies

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Type 2 diabetes: principles of pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Cardiovascular actions of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Prevalence of Overweight and Obesity in the United States, 2007-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

Beneficial Effects of PKF275-055, a Novel, Selective, Orally Bioavailable, Long-Acting Dipeptidyl Peptidase IV Inhibitor in Streptozotocin-Induced Diabetic Peripheral Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-016-0813-X

10.1007/S12272-016-0813-X

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

27502601

Dimensions Publication ID

7 September 2017

1007765618

0 references

Fatcat ID

release_5milylh3mjdrbfwjlas5ojavwu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5milylh3mjdrbfwjlas5ojavwu

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

27502601

1 reference

PubMed ID

27502601